NCT01053104已完成不适用
Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring Pilot Study of Optimal Dose Scheduling of Capecitabine for Patients With Metastatic Colorectal or Metastatic Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Toxicities (frequency at each of grades 2, 3 and 4, over all cycles)
研究概览
简要总结
To develop a system to manage side effects and adjust chemotherapy dose such that a patient can receive their personal maximum tolerated dose.
详细描述
Patients with metastatic colorectal or breast cancer will be recruited.
- Metastatic Colorectal Cancer: capecitabine alone or capecitabine + oxaliplatin for 8 3-week cycles
- Metastatic Breast Cancer: capecitabine alone or capecitabine + docetaxel for 8 3-week cycles.
All patients will be given a mobile phone onto which they will enter any side-effects experienced prior to taking capecitabine in the morning and evening. Any grade 3 or 4 symptoms will trigger an alert to a pager held by the ward-staff for immediate attention. Thus, patients' severe side-effects will be monitored in real time and the trial will allow real-time dose reductions during cycles and dose-increases at clinics. Patient experience in the trial will also be evaluated during their participation in the trial.
Patients will already be receiving the drug prior to this study and will not be administered to patients as part of this study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic colorectal or breast cancer patients commencing treatment on one of four specified regimens
- •For metastatic colorectal cancer:
- •capecitabine 2000mg/m2 d 1-14, q 3 weekly and oxaliplatin 130mg/m2 d1 q 3 weekly (CAPOX)
- •capecitabine 2500mg/m2 d 1-14, q 3 weekly
- •For metastatic breast cancer:
- •capecitabine 2000mg/m2d 1-14, q 3 weekly
- •capecitabine 2000mg/m2 d 1-14, q 3 weekly and docetaxel 75mg/m2 d1 q 3 weekly
- •Age > 18 years
- •Fit to start at full (100%) starting dose of all drugs
- •Able and willing to use mobile phone
- •Reasonable renal, liver and bone marrow function
- •Absolute neutrophil count (ANC) >1.5 x 109/L
- •Platelet count > 100 x 109/L
- •Total bilirubin <1.5 ULN
- •ALT, AST < 2.5 x ULN
- •Alkaline phosphatase < 2.5 x ULN
- •No obvious contra indications to capecitabine or oxaliplatin or docetaxel
- •Patients must also be able to read, write and understand English.
排除标准
- •Patients who live in an area of no Vodafone or Orange mobile phone network - - Patients participating in other cancer treatment trials
- •Moderate or severe renal impairment [creatinine clearance <30ml/min (calculated according to Cockroft-Gault formula)]
结局指标
主要结局
Toxicities (frequency at each of grades 2, 3 and 4, over all cycles)
时间窗: At the end of each cycle and at occurrence
次要结局
- Number of inappropriate dose adaptations and self care advice messages generated ['inappropriate' defined by nurse overriding generated advice(At occurrence)
- Frequency of patients receiving each piece of advice from the system, including recommendations on dose and on self-treating side effects.(At occurrence)
- Obtain descriptive information on amount and duration of drug delivery (stage 2 only) Number of patients who, dose reduce stay at same dose dose increase Total dose delivery Chemotherapy duration(Twice daily)
- Obtain feedback from staff on using the system Staff recommendations for changes or improvements to the system throughout the course of the study and Semi-structured interviews(weekly for staff recommendations and one semi structured interview will take place)
- Test and refine mobile phone and server software systems Frequency of occurrence of technological faults (for example, problems caused by no phone reception)(At occurrence)
- Patient Experience EvaluationPatient experience will be evaluated as detailed in Patient Experience Evaluation(At least twice during their participation in the trial but not all patients may need to be interviewed)
- Evaluate safety outcomes Total number of grade 3/4 toxicities throughout the study period Degree of toxicity experienced Number of alerts, split by severity(End of each cycle and at occurrence)
- Dose intensity in mg/m2/week and toxicities as for stage 1(Once at the end of the study for each patient)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Using mHealth to Optimize Pharmacotherapy RegimensSchizophreniaFirst-Episode PsychosisNCT04248517New York State Psychiatric Institute23
已完成
2 期
Automated Telephone Monitoring for Symptom ManagementCarcinomaNCT00799084Michigan State University526
进行中（未招募）
不适用
Telehealth and Memory StudyChemotherapy-related Cognitive DysfunctionNCT04586530University of Pittsburgh220
已完成
不适用
Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With CancerAdherence to Medication RegimeCancerNCT02157519Massachusetts General Hospital212
已完成
不适用
Early Prototyping and Usability Testing (ACPS)Medication AdherenceNCT05719064Children's Hospital Los Angeles22